会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明公开
    • NOD2의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물
    • 包含用NOD2激动剂或其培养物处理的干细胞用于预防和治疗免疫缺陷病毒和炎症疾病的药物组合物
    • KR1020140019461A
    • 2014-02-14
    • KR1020140009917
    • 2014-01-27
    • 주식회사 강스템바이오텍
    • 강경선김형식
    • A61K38/03A61K38/05A61K35/12A61P37/00
    • A61K35/28A61K35/545A61K38/05C12N5/0665C12N2501/02C12N2501/05C12N2501/052C12N2501/054
    • The present invention relates to a pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing the stem cells which are obtained by adding an NOD2 agonist to stem cells which express NOD2 and culturing the stem cells, or cultured product thereof, and more specifically, to a method for suppressing the immune diseases or inflammatory diseases of a subject, comprising the step of administering the pharmaceutical composition, the stem cell or a cultured product thereof to a subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or a cultured product thereof, a method for preparing PGE2 or TGF-β1, comprising the step of adding an NOD2 agonist to stem cells which express NOD2 and culturing the stem cells, a graft comprising stem cells which express NOD2 and an NOD2 agonist, a preparation method of the graft, a composite comprising stem cells which express NOD2 and an NOD2 agonist, and a cultured product obtained by adding an NOD2 agonist to stem cells which express NOD2. The pharmaceutical composition according to the present invention is a cell therapy product which has no side effect and can be used economically to replace existing immunosuppressive drugs or anti-inflammatory drugs having known side effects. Therefore, the present invention can be used to prevent or treat immune diseases and infectious and inflammatory diseases such as Crohn disease, rheumatoid arthritis and atopic dermatitis which are autoimmune diseases.
    • 本发明涉及一种预防或治疗免疫疾病或炎性疾病的药物组合物,其含有通过向表达NOD2的干细胞培养NOD2激动剂或其培养产物,更具体地提供的干细胞 涉及抑制受试者的免疫疾病或炎症性疾病的方法,包括向受试者施用药物组合物,干细胞或其培养物的步骤,制备免疫抑制药物或抗炎药物的方法 使用干细胞或其培养产物,制备PGE2或TGF-β1的方法,包括向表达NOD2的干细胞和培养干细胞的干细胞中加入NOD2激动剂的步骤,包含表达NOD2的干细胞和 NOD2激动剂,移植物的制备方法,包含表达NOD2和NOD2激动剂的干细胞的复合物,以及培养物 通过向表达NOD2的干细胞中加入NOD2激动剂获得的红色产物。 本发明的药物组合物是没有副作用的细胞治疗产品,可以经济地用于替代现有的具有已知副作用的免疫抑制药或抗炎药。 因此,本发明可用于预防或治疗诸如克罗恩病,类风湿性关节炎和特应性皮炎的免疫疾病和感染性和炎性疾病,其为自身免疫性疾病。
    • 6. 发明公开
    • 개과 동물의 와튼 젤리-유래 중간엽 줄기세포의 분리 및 특성화
    • 卡介苗可以分离和表征糖蛋白衍生的间充质干细胞
    • KR1020130028294A
    • 2013-03-19
    • KR1020110091746
    • 2011-09-09
    • 주식회사 강스템바이오텍
    • 강경선서민수박상범
    • C12N5/0775C12N1/38A61K35/12
    • PURPOSE: Separation and characterization of watton jelly-originated mesenchyme stem cell of canine are provided to have capability of differentiating cultured cell into ectoderm, mesoderm, or endoderm originated cell by culturing stem cell separated from watton jelly of canine and animals. CONSTITUTION: As for the separation and characterization of watton jelly-originated mesenchyme stem cell of canine, stem cell separated from the watton jelly of canine and animal is cultured. The cultivated cell is collected. The characteristics of preparation method of multipotent stem cell of watton jelly of canine and animal are as follows. The immunological characteristics of negative are shown to CD3, CD11c, CD28, CD34, CD38, CD45, CD41a, and CD62L as a human marker, and the immunological characteristics of positive are shown to CD90 and CD105 as a human marker. The cell has the capability of differentiating into ectoderm, mesoderm, or endoderm originated cells. The cell has the cultivation capability of undivided condition with passage vaccination of 14 or more. The canine and animal are selected from dog, cornice lupus, coyote, jackal, and fox.
    • 目的:通过培养从犬和动物的沃尔特胶中分离出的干细胞,提供犬的维特灵果胶起源的间充质干细胞的分离和表征,以将培养细胞分化成外胚层,中胚层或内胚层起源的细胞。 构成:对犬牙ton原源间充质干细胞的分离和表征进行分析,分离犬和动物的沃特顿果冻干细胞。 收集培养的细胞。 犬和​​动物的沃顿果冻多能干细胞制备方法的特点如下。 显示为CD3,CD11c,CD28,CD34,CD38,CD45,CD41a和CD62L作为人标记物的阴性免疫特征,阳性的免疫学特征显示为CD90和CD105作为人类标记。 细胞具有分化为外胚层,中胚层或内胚层起始细胞的能力。 细胞具有不分割条件的培养能力,通过疫苗接种14次以上。 狗和动物选自狗,檐口狼疮,土狼,豺狼和狐狸。